Skip to main content
. 2024 Jan 19;4(5):100470. doi: 10.1016/j.xops.2024.100470

Table 1.

Clinical and Demographic Characteristics of Dataset 1

Training Set (n = 483)
Test Set (n = 56)
PR Failure
PR Success
PR Failure
PR Success
n = 153 (31.7%) n = 330 (68.3%) n = 30 (53.6%) n = 26 (46.4%)
Mean age (SD) 62.4 (12.1) 64.0 (10.4) 62.4 (10.3) 60.5 (8.3)
Sex
 Female 48 (31.4%) 121 (36.7%) 17 (56.7%) 13 (50.0%)
 Male 104 (68.0%) 209 (63.3%) 13 (43.4%) 13 (50.0%)
 Missing 1 (0.6%) 0 (0%) 0 (0%) 0 (0%)
Procedure experience
 < 16 cases 133 (86.9%) 231 (70.00%) 26 (86.7%) 10 (38.5%)
 > 16 cases 4 (2.6%) 25 (7.6%) 4 (13.3%) 16 (61.5%)
 Missing 16 (10.5%) 74 (22.4%) 0 (0%) 0 (0%)
Lens status
 Aphakic 1 (0.6%) 0 (0.00%) 7 (23.3%) 3 (11.5%)
 Phakic 102 (66.7%) 244 (73.9%) 13 (43.3%) 7 (26.9%)
 Pseudophakic 50 (32.7%) 86 (26.1%) 10 (33.3%) 16 (61.5%)
Macula status
 Detached 76 (49.7%) 112 (33.9%) 20 (66.7%) 5 (15.4%)
 Attached 76 (49.7%) 218 (66.1%) 10 (33.3%) 22 (84.6%)
 Missing 1 (0.6%) 0 (0%) 0 (0%) 0 (0%)
Size of RRD
 < 4 clock hours 64 (41.8%) 194 (58.8%) 9 (30.0%) 23 (88.5%)
 > 4 clock hours 87 (56.9%) 130 (39.4%) 21 (70.0%) 3 (11.5%)
 Missing 2 (1.3%) 6 (1.8%) 0 (0%) 0 (0%)
Number of retinal breaks (SD) 1.34 (0.74) 1.35 (0.95) 1.4 (0.6) 1.1 (0.4)
Inferior break
 Absent 142 (92.8%) 313 (94.9%) 25 (83.3%) 25 (96.1%)
 Present 2 (1.3%) 3 (0.9%) 5 (16.7%) 1 (3.9%)
 Missing 9 (5.9%) 14 (4.2%) 0 (0%) 0 (0%)
Vitreous hemorrhage
 Absent 134 (87.6%) 293 (88.8%) 18 (60.0%) 26 (100%)
 Present 19 (12.4%) 37 (11.2%) 12 (40.0%) 0 (0)
Lattice degeneration
 Absent 117 (76.5%) 273 (82.7%) 21 (70.0%) 22 (84.6%)
 Present 34 (22.2%) 57 (17.3%) 9 (30.0%) 4 (15.8%)
 Missing 2 (1.3%) 0 (0.00%) 0 (0%) 0 (0%)

PR = pneumatic retinopexy; RRD = rhegmatogenous retinal detachment; SD = standard deviation.

Comprised of 483 patients (training set), captured from Emami-Naeini et al database8 and the test set (n = 56) comprised of patient records captured from the UC Davis electronic medical records that underwent pneumatic retinopexy (PR) by procedure outcome at 3-month follow-up.